With mass vaccinations launched across the world, investors’ optimism pushed markets to the all-time high in January.
However, it soon became clear that there are major issues that still remain to be resolved: from vaccine production and transportation, to convincing people of their safety and efficacy. This realization raised the tension in the markets, so when a little “black swan” - the “rebellion” of Robinhood traders – happened, markets underwent a correction and VIX sharply jumped and remained at an elevated level of over 30 during the last week of January.
Tactical Asset Allocation
Liquidity |
Neutral |
Bonds |
Underweight |
Equities |
Neutral |
Alternative Investments |
Overweight |
Macroeconomics
With a Democratic Majority in the US Senate, it is likely that a new large stimulus package is going to be passed. However, it might still end up smaller than the ambitious $1.9tn proposed by President Biden, since some Republican votes are needed to pass the bill and their proposed package is much more modest: $618bn. Therefore, investors are closely watching for the outcome of negotiations.
As the economic situation on both sides of the Atlantic is still strained and a double-dip recession in Eurozone is likely, markets are concerned of the possibility of an unexpected premature tapering by central banks, which is why the Fed’s repeated message, including the one in the January meeting, has been that no change in asset purchases is planned so far and that there will be a lot of guidance before it actually happens. Similarly, at the last meeting, the ECB kept the rates and asset purchases unchanged, since it is not expecting the inflation in the EU to raise above 2% in the coming months.
Fixed Income
The US Treasury yields rose in the first half of January on the vaccination optimism, but amid the risk-off mood in the second half of January, the yields briefly dropped below 1%, although did not stay at that level long and went up to 1.13% on February 3rd. Moreover, the US Treasury yield curve is at its steepest level since 2016, which means that the rates market remains optimistic about the upcoming recovery even despite the correction in the equity market.
Similar behaviour we saw in Emerging Markets but not to the same extend. We like the sector as it still has some potential to perform, especially with the current raise in oil-price.
With an expected vaccine roll out in 1H21, provided support from central banks and fiscal stimulus continues, we expect the hunt for yield to continue with higher beta names outperforming.
Despite lagging in January, Emerging Markets still remain attractive in light of improving commodity consumption. Issuance of new bonds in January was at a record level, with governments and companies trying to lock in low interest rates, especially for (ultra-)long maturities. Investors were eager to buy the new bonds, signaling confidence in the Fed’s intention not to start tapering in the upcoming months.
Equities
Beginning of mass vaccinations across the globe, accompanied by the prospect of a new large US stimulus bill extended the year-end equity rally into the first half of January and gave a push to pro-cyclical rotation. However, problems in vaccine production and distribution - especially in Europe - amid the still raging virus gave investors a reality check, so the markets fell in the second half of January erasing most of the month’s gains. Eurozone was hit especially badly, while emerging markets, namely China, showed positive performance.
In light of prolonged lockdowns in Europe, large tech and healthcare stocks once again fared better than the more cyclical ones. However, consumer staples, as a typical defensive sector, was one of the losers in January, which shows investors’ willingness to prepare for a recovery despite the short-term uncertainty.
Equity Indicators
Valuation |
Neutral |
Momentum |
Neutral |
Seasonality |
Positive |
Macro-Economics |
Neutral |
Alternatives
Gold price fell in January in line with the risk-on mood, but during the end-of-January correction, it failed to regain the losses and got stuck around 1850. This is partially due to the strengthening of USD, propelled by the large fiscal stimulus prospects and the European vaccination lags. Nonetheless, EUR/USD is yet expected to rise in the next months.
Oil prices rose in January on the expectation that OPEC+ will adhere to their production quotas amid clearer economic recovery prospects. The oil futures prices now are in backwardation, indicating that currently demand is picking up and travel and production are on course for recovery.
Note: This report is published by Clarus Capital Group AG

Roger Ganz, Head Asset Management, Clarus Capital Group AG
Dejan Ristic, Partner, Clarus Capital Group AG
Disclaimer
This document has been prepared by Clarus Capital Group AG ("Clarus Capital"). This document and the information contained herein are provided solely for information and marketing purposes. It is not to be regarded as investment research, sales prospectus, an offer or a solicitation of an offer to enter in any investment activity or contractual relation. Please note that Clarus Capital retains the right to change the range of services, the products and the prices at any time without notice and that all information and opinions contained herein are subject to change.
This document is not a complete statement of the markets and developments referred to herein. Past performance and forecasts are not a reliable indicator of future performance. Investment decisions should always be taken in a portfolio context and make allowance for your personal situation and consequent risk appetite and risk tolerance. This document and the products and services described herein are generic in nature and do not consider specific investment objectives, financial situation or particular needs of any specific recipient. Investors should note that security values may fluctuate, and that each security’s price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Individual client accounts may vary. Investing in any security involves certain risks called non-diversifiable risk. These risks may include market risk, interest-rate risk, inflation risk, and event risk. These risks are in addition to any specific, or diversifiable, risks associated with particular investment styles or strategies.
Clarus Capital does not provide legal or tax advice and makes no representations as to the tax treatment of assets or the investment returns thereon, either in general or with reference to specific client's circumstances and needs. Recipients should obtain independent legal and tax advice on the implications of the products and services in the respective jurisdiction before investing. Certain services and products are subject to legal provisions and cannot be offered world-wide on an unrestricted basis. In particular, this document is not intended for distribution in jurisdictions where its distribution by Clarus Capital would be restricted. Clarus Capital specifically prohibits the redistribution of this document in whole or in part without the written permission of Clarus Capital and Clarus Capital accepts no liability whatsoever for the actions of third parties in this respect. Neither Clarus Capital nor any of its partners, employees or finders accepts any liability for any loss or damage arising out of the use of all or any part of this document. Source of all information is Clarus Capital unless otherwise stated. Clarus Capital makes no representation or warranty relating to any information herein which is derived from independent sources. Please consult your client advisor if you have any questions.